

content-type: multipart/related,type="text/html",boundary="-----
=_chiikat_10f_4be4_edc54017_95baa0aa_REL"
MIME-Version: 1.0
Received: Sat, 12 Jan 2008 18:34:31 +0000
content-type: text/html; charset="windows-1252"
content-transfer-encoding: quoted-printable

From: Birkett, Geoff

Sent: Friday, September 16, 2005 7:53 PM

To: Morris, Amy; Beamish, Don G; Rastad, Jonas; Fitzsimons, Carolyn;
Dunscombe, Nick M; Nordstrom, Eva (Seroquel); Brecher, Martin; Rance,
Mike J; Blair, Mina L; Hunt, Jonathan; Major, Chris S (STAN); Brown,
Steve W; McCaffrey, Edel; Marland, Louise A; Saunders, Julie; Hoegstedt,
Johan; Scott, Mark S (Wilmington); Manning, Julia; Dillione, Michelle T;
Murray, Michael F; Lampert, Steve B; Nicoli, David P; Seage, Edward C;
Peipher, Charles R; Gionta, Lynn; Minnick, Jim G; Domine, Lisa I;
Gormley, Glenn J; Stafflage, Angelika; McCormack, Eileen
Subject: Re: CATIE KEY MESSAGES - CONFERENCE CALL GOING ON NOW - Amy

Team


The no 1 message is.....

We are pleased with the outcome.

It confirms the unique profile of Seroquel and that our brand has an ideal combination of efficacy and excellent tolerability.

That's why Seroquel is the no 1 agent.

Apologies for wading in - but I want this headline - not a long list of bullets.



G

-----Original Message-----

From: Morris, Amy <Amy.Morris@astrazeneca.com>

To: Beamish, Don G <Don.Beamish@astrazeneca.com>; Birkett, Geoff <geoff.birkett@astrazeneca.com>; Rastad, Jonas <Jonas.Rastad@astrazeneca.com>; Fitzsimons, Carolyn <Carolyn.Fitzsimons@astrazeneca.com>; Dunscombe, Nick M <Nick.Dunscombe@astrazeneca.com>; Nordstrom, Eva (Seroquel) <Eva.Nordstrom@astrazeneca.com>; Brecher, Martin <martin.brecher@astrazeneca.com>; Rance, Mike J <Mike.Rance@astrazeneca.com>; Blair, Mina L <Mina.Blair@astrazeneca.com>; Hunt, Jonathan <Jonathan.Hunt@astrazeneca.com>; Major, Chris S (STAN) <Chris.S.Major@astrazeneca.com>; Brown, Steve W <Steve.Brown@astrazeneca.com>; McCaffrey, Edel <Edel.McCaffrey@astrazeneca.com>; Marland, Louise A <Louise.Marland@astrazeneca.com>; Saunders, Julie <Julie.Saunders@astrazeneca.com>; Hoegstedt, Johan <Johan.Hoegstedt@astrazeneca.com>; Scott, Mark S (Wilmington) <mark.scott@astrazeneca.com>; Manning, Julia <Julia.Manning@astrazeneca.com>; Dillione, Michelle T <michelle.dillione@astrazeneca.com>; Murray, Michael F <michael.murray@astrazeneca.com>; Lampert, Steve B <steve.lampert@astrazeneca.com>; Nicoli, David P <David.Nicoli@astrazeneca.com>; Seage, Edward C <edward.seage@astrazeneca.com>; Peipher, Charles R <charles.peipher@astrazeneca.com>; Gionta, Lynn <Lynn.Gionta@astrazeneca.com>; Minnick, Jim G <jim.minnick@astrazeneca.com>; Domine, Lisa I <Lisa.Domine@astrazeneca.com>; Gormley, Glenn J <Glenn.Gormley@astrazeneca.com>; Stafflage, Angelika <Angelika.Stafflage@astrazeneca.com>; McCormack, Eileen <Eileen.McCormack@astrazeneca.com>

Sent: Fri Sep 16 14:48:46 2005

Subject: CATIE KEY MESSAGES - CONFERENCE CALL GOING ON NOW - Amy

Amy Morris

AstraZeneca Pharmaceuticals LP

Communications & External Relations

Office: (302) 885-3572

Fax: (302) 886-4885